Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Pemetrexed 24Nivolumab 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Fluorouracil 14Capecitabine 14atezolizumab 13Docetaxel 13trastuzumab deruxtecan 12durvalumab 12Trastuzumab 12Lenalidomide 12daratumumab 11Cytarabine 11olaparib 10Prednisone 10Bortezomib 10Bevacizumab 10130-nm albumin-bound paclitaxel 10Doxorubicin 9venetoclax 8Oxaliplatin 8Crizotinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has announcements × pomalidomide × Clear all
NCT05083169 2026-05-08

MajesTEC-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
587 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

European Myeloma Network B.V.

Phase 3 Completed
304 enrolled 19 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
240 enrolled 1 FDA
Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Sanofi

Phase 3 Completed
307 enrolled 32 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡